{"id":"montelukast-low-feno-group","safety":{"commonSideEffects":[{"rate":"18","effect":"Headache"},{"rate":"4","effect":"Influenza-like illness"},{"rate":"3","effect":"Abdominal pain"},{"rate":"2","effect":"Cough"},{"rate":null,"effect":"Neuropsychiatric events (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Montelukast is a selective antagonist of the cysteinyl leukotriene type-1 (CysLT1) receptor. Leukotrienes are inflammatory mediators released by mast cells and eosinophils that promote airway constriction, mucus secretion, and eosinophil recruitment. By blocking these receptors, montelukast reduces inflammation and improves airflow in asthmatic patients, particularly those with low fractional exhaled nitric oxide (FeNO), suggesting a non-eosinophilic phenotype.","oneSentence":"Montelukast blocks cysteinyl leukotriene receptors (CysLT1) to reduce airway inflammation and bronchoconstriction in asthma.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:55:47.931Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (maintenance and acute treatment)"},{"name":"Allergic rhinitis"},{"name":"Exercise-induced bronchoconstriction"}]},"trialDetails":[{"nctId":"NCT02479074","phase":"PHASE4","title":"The Utility of feNO in the Differential Diagnosis of Chronic Cough","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2016-01","conditions":"Cough","enrollment":49}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Montelukast"],"phase":"marketed","status":"active","brandName":"Montelukast (Low FeNO group)","genericName":"Montelukast (Low FeNO group)","companyName":"Hull University Teaching Hospitals NHS Trust","companyId":"hull-university-teaching-hospitals-nhs-trust","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Montelukast blocks cysteinyl leukotriene receptors (CysLT1) to reduce airway inflammation and bronchoconstriction in asthma. Used for Asthma (maintenance and acute treatment), Allergic rhinitis, Exercise-induced bronchoconstriction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}